MedPath

Heart Test Laboratories

🇺🇸United States
Ownership
-
Employees
15
Market Cap
-
Website
Introduction

Heart Test Laboratories, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

Clinical Trials

2

Active:2
Completed:0

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

Not Applicable
Active, not recruiting
Conditions
Health Screening
First Posted Date
2022-05-06
Last Posted Date
2023-09-21
Lead Sponsor
Heart Test Laboratories, Inc.
Target Recruit Count
50
Registration Number
NCT05364541
Locations
🇺🇸

University of Texas Medical Center, Dallas, Texas, United States

MyoVista wavECG Clinical Validation Study Versus Low e' on Echocardiogram

Active, not recruiting
Conditions
Cardiac Disease
First Posted Date
2021-03-18
Last Posted Date
2023-09-21
Lead Sponsor
Heart Test Laboratories, Inc.
Target Recruit Count
575
Registration Number
NCT04804969
Locations
🇺🇸

Scripps Memorial Hospital, La Jolla, California, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Montefiore Medical Center, Bronx, New York, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.